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KEY POINTS
 Pulmonary hypertension is frequent in systemic sclerosis and is associated with poor prognosis.
 Pulmonary hypertension occurs as a result of a pulmonary arteriopathy but also can be a conse-
quence of interstitial lung disease and/or left heart involvement.
 These phenotypes may be difficult to differentiate and often overlap, complicating both the diag-
nosis and the follow-up.
 An integrated multidisciplinary approach, including a rheumatologist, cardiologist, and pulmonolo-
gist, is mandatory to improve patients’ management.INTRODUCTION
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Gargani et al272(RHC).3 In patientswith SSc, PH can be the result of
an isolated pulmonary arteriopathy, determining a
condition of pulmonary arterial hypertension
(PAH), a relevant cause of morbidity in SSc.4 It is
included in the first group of the new clinical classi-
fication of PH, characterized by precapillary PH
with pulmonary artery wedge pressure
(PAWP) less than or equal to 15 mm Hg.3
Elevated pulmonary artery pressure (PAP) in
SSc also may occur, however, as a consequence
of interstitial lung disease (ILD) or left ventricular
(LV) systolic and/or diastolic dysfunction.5 In these
situations, the term PAH is not correct and the
more generic term PH should be used. It is also
true that an overlap between the different etiol-
ogies of PH is possible and likely frequent in SSc
patients; therefore, it is important to distinguish
the hemodynamic contribution of the diverse
mechanisms, which are linked to different thera-
peutic and prognostic correlates.
DIFFERENT ETIOLOGIES OF PULMONARY
HYPERTENSION IN SYSTEMIC SCLEROSIS
The pathophysiology of the mechanisms leading to
the onset of PH is complex, with interplay between
inflammation process, autoimmunity, and systemic
vasculopathy. Some overlap within different sub-
types of PH may exist, because this condition
shows a pathophysiologic continuum,6 which is
particularly evident in SSc patients, who can pre-
sent with several forms of PH during the course
of the disease. Themost typical form was tradition-
ally believed PAH, group I, according to the most
recent European and American guidelines.3,7
Group II (PH due to left heart disease) and group
III (PH due to lung disease and/or hypoxia), how-
ever, also can be present in SSc patients. In the
Pulmonary Hypertension Assessment of Recogni-
tion of Outcomes Registry of Scleroderma
(PHAROS), SSc patients with PH were classified
as group I PAH in 69% of cases, group II PH in
10%of cases, and group III PH in 21%of patients.8
Rarely, pulmonary veno-occlusive disease (PVOD)
may also be present in SSc patients.9
Pulmonary Arterial Hypertension
According to the2015EuropeanGuidelines3 onPH,
PAH is defined by a mean PAP (mPAP) of greater
than or equal to 25 mm Hg with a PAWP of less
than or equal to 15mmHg at RHC and a pulmonary
vascular resistance (PVR) of greater than 3 Wood
units with either normal or reduced cardiac output
(CO)10 in absence of other forms of precapillary
PH. The prevalence of PAH in SSc is reported as
8% to 12% in the European League Against Rheu-
matism (EULAR) Scleroderma Trials and ResearchGroup database.2 Nevertheless, a recent study
confirms a lower prevalence of PH in Italy
compared with Anglo-Saxon cohorts.11 Moreover,
it ranges from 0.5% to 15% based on RHC diag-
nosis in different studies.12–14 PAH greatly affects
morbidity and mortality in these patients, respon-
sible for almost 30% of SSc-related deaths.2 SSc
patients with PAH have a significantly worse 3-
year survival compared with SSc patients without
PAH.15 It is debated whether SSc-PAH is less
responsive to specific vasoactive therapies than
patients with idiopathic PAH,16–18 because data
from randomized trials indicate that more intensive
treatments—especially combination therapy—
would gain similar benefits in SSc-associated
PAH compared with other forms of PAH.19–23 One
of the reasons given to explain the suboptimal effi-
cacy of PAH treatment, highlighted in somestudies,
is that drugs are started too late in the course of the
disease, due to delay in diagnosis. Signs and
symptoms of PAH are generally nonspecific and
underestimated, because they are often not
discriminated from general SSc symptoms, post-
poning the diagnosis to more advanced phases of
the disease, characterized by structural and irre-
versible damage of the pulmonary vasculature. It
has been shown that patients identified with PAH
via an active screening programhave a better prog-
nosis than those diagnosed in the course of routine
clinical practice,24 underlining the potential benefit
of early diagnosis and early intervention in the
course of the pathologic process.
PVOD is a rare form of PH, with a prevalence of
0.1 to 0.2 per million persons per year. From a his-
tologic point of view it is characterized by fibrotic
occlusion of postcapillary venules. In the 2015 Eu-
ropean Society of Cardiology Guidelines3, PVOD
has been classified, together with pulmonary
capillary hemangiomatosis, in a specific subgroup
next to PAH, because of the similar pathologic, ge-
netic and clinical features.3 PVOD may complicate
SSc,25,26 although a recent study showed that
radiological signs of PVOD seem less common in
SSc-PAH than previous reports suggest. They
correlate, however, with a worse prognosis, and
clinicians should be aware of the risk of noncardio-
genic pulmonary edema induced by PAH-specific
therapy.9 Portal hypertension can also occur in pa-
tients with hepatobiliary involvement, which is not
infrequent in SSc.5,27Pulmonary Hypertension Due to Lung
Disease
ILD is common in both diffuse and limited cuta-
neous SSc, with clinical manifestations in ap-
proximately 40% of patients.28 When ILD is
Systemic Sclerosis 273complicated by PH, the prognosis of patients
worsens significantly.15,29–31 Mathai and col-
leagues30 showed that PH associated with ILD
(PH-ILD) in SSc patients was linked to a 5-fold
increased risk of death compared with SSc-PAH.
These data were confirmed in another recent large
study by Condliffe and colleagues,15 where the 3-
year survival was shown significantly worse in
SSc patients with PH-ILD, compared with patients
with isolated SSc-PAH. The pathogenic basis of
PH-ILD is multifactorial, including fibrotic destruc-
tion of the pulmonary vasculature andparenchyma,
vascular remodeling due to chronic hypoxia, and
diffuse specific vasculopathy similarly to that
observed in isolated SSc-PAH.31,32
An article by Launay and colleagues33 published
in 2011 shed some light on the clinical and prog-
nostic characteristics of PH-ILD in SSc. Patients
with PH-ILD were more likely to be younger male
patients, with the diffuse cutaneous form of the dis-
ease, more frequent with antitopoisomerase, and
less frequent anticentromere antibodies, with a
lower PaO2 and a worse prognosis compared with
SSc-PAH. Pericardial effusion and diffusion ca-
pacity for carbon monoxide (DLCO), with a cutoff
of 30%, were the only 2 prognostic determinants
in the PH-ILD group, whereas mPAP was not,
consistent with previous data.30 Usually, in pa-
tients with COPD or ILD unrelated to SSc, PH is
generally mild, and when mPAP is greater than
35 mm Hg, it is considered too high to be entirely
due to ILD. The prognosis for patients with mild
PH-ILD in this study was as poor as for patients
with moderate to severe PH-ILD.33 Because SScFig. 1. The spectrum of PH phenotype in SSc patients. CI,
ond; PaO2, partial pressure of O2 in arterial blood; TLC, tois frequently associated with ILD, in a patient with
SSc with both PH and ILD, it can be difficult to
firmly establish whether the patient has a PAH in-
dependent from ILD, a PH-ILD, or the combination
of PH-ILD and a pulmonary vasculopathy (Fig. 1).
Combined pulmonary fibrosis and emphysema
syndrome (CPFE) can also be a cause of PH in
SSc34 and is associated with poor prognosis. It is
characterized by combined emphysema of the up-
per lobes and fibrosis of the lower lobes on chest
CT, with preserved lung volumes, impaired DLCO,
and hypoxemia at exercise and at rest in advanced
cases. Whereas in the general population CPFE is
usually observed in smokers, in SSc patients this
condition is also present in nonsmokers.35Pulmonary Hypertension Due to Left Heart
Disease
Cardiac involvement in SSc is frequent and rele-
vant from a prognostic point of view.36 Although
the real incidence is highly variable because it de-
pends on the definition of cardiac involvement and
on the diagnostic tools used to detect it, cardiac
magnetic resonance37,38 and autoptic studies39
report percentages up to 75%. Therefore, it is diffi-
cult to exclude patients with any kind of left heart
abnormality when assessing PH in SSc.40
In a retrospective population of 107SSc patients,
Fox and colleagues41 evaluated all subjects with
suspectedPHby right and left heart catheterization,
assessing LV end-diastolic pressure (LVEDP) mea-
surement prefluid and postfluid challenge. The
study found a high prevalence of postcapillarycardiac index; FEV1, forced expiratory volume in 1 sec-
tal lung capacity.
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PAWP >15 mm Hg, and normal or reduced CO),
including a significant number of occult postcapil-
lary PH (mPAP 25 mm Hg, PAWP 15 mm Hg,
LVEDP >15 mm Hg before or after a 500-mL fluid
challenge administered over 5–10 min). Although
RHC is the gold standard for assessment of intra-
cardiac andpulmonary pressures, some controver-
sial issues remain. In a large cohort of 11,523
patients undergoing simultaneous right heart and
left heart catheterization, Halpern and Taichman42
found a high percentage of patients with a signifi-
cant discrepancy between PAWP and LVEDP
(PAWP<15mmHgandLVEDP>15mmHg). There-
fore, approximately half of thepatients presumed to
havePAHbasedonPAWPwere found tohavepost-
capillary PH based on LVEDP. It is known that
PAWP and LVEDP are not identical: a compliant
left atrium can protect the pulmonary vasculature
from elevated LVEDP, whereas a stiff left atrium
can result in postcapillary PH in the setting of a
normal LVEDP.40,43 Moreover, filling pressures
vary over time, as shown in the Registry to Evaluate
Early and Long-term Pulmonary Arterial Hyperten-
sion Disease Management (REVEAL) database,
where 10% of patients with an initial PAWP less
than or equal to 12 mm Hg had a follow-up PAWP
of greater than or equal to 16 mm Hg, whereas
50% of patients with an initial PAWP greater than
or equal to 16 mm Hg had a follow-up PAWP less
than or equal to 12 mm Hg.44 Altogether, these
data highlight the discrepancies that may occur be-
tween PAWP and LVEDP, which reflect the
complexity of diagnosing pulmonary vascular dis-
ease in the presence of left heart abnormalities40;
a significant overlap between PAH and PH due to
left heart disease—which is frequent in SSc—
makes a straightforward differentiation between
the 2 conditions not always feasible6 and the man-
agement uncertain.THE NEED FOR EARLY DIAGNOSIS—A
MULTIPARAMETRIC APPROACH
Many attempts have been made in the past few
years to establish a reliable way to identify the
subgroup of SSc patients prone to developing
PAH early, given the availability of more effective
PAH-specific therapies and the evidence that
patients identified early through an active
screening program have better survival than pa-
tients identified during routine clinical care.24
The European Guidelines recommend resting
echocardiography as a screening test in asymp-
tomatic SSc patients, followed by annual
screening with echocardiography, DLCO, and
biomarkers.3Echocardiography
Echocardiography is the routine imaging tool to
noninvasively assess the right heart and pulmonary
circulation unit.45 Although RHC remains the gold
standard for confirming diagnosis and supporting
treatment decisions, echocardiography has the
advantage of being widely available, cost-
effective, and well tolerated. A thorough cardiac ul-
trasound examination should include not only the
indirect estimation of systolic PAP (sPAP), which
is essential in symptomatic patients with a clinical
suspicion of PH to establish the probability of this
condition, but also a detailed evaluation of the right
and left heart dimensions and function as well as
pulmonary artery diameter and inferior vena cava
size and collapsibility. It is only by an accurate
description of the 4 chambers’ anatomic and func-
tional characteristics that it is possible to attempt a
prediction of precapillary versus postcapillary PH46
(Table 1). A careful assessment of the right heart is
often neglected in routine echocardiograms,
despite its relevance, not only in connective tissue
disease (CTD).45 An adequate echocardiogram
should include a right ventricular (RV)-focused api-
cal 4-chamber view, which would reduce the vari-
ability in how the right heart is sectioned and,
consequently, in RV dimensions and areas.47 For
the right atrium (RA), as well for the left atrium, vol-
umes or at least areas, are more accurate to deter-
mine the chamber size compared with linear
dimensions. The European Guidelines include an
end-systolic RA area greater than 18 cm2 as one
of the echocardiographic signs suggestive of PH,
to be used to assess the probability of PH in addi-
tion to tricuspid regurgitation (TR) velocity.3 The ac-
celeration time (ACT) of the RV outflow tract (RVOT)
is another simple measurement that should be
assessed: when less than 105 milliseconds and/
or showing a midsystolic notch in the Doppler pro-
file, it is considered a suggestive sign of PH,3 as an
indirect marker of increased PVR.48,49
It is now well established that there is a poor RV
adaptation to overload in SSc compared with other
CTDs,50 which is also linked to a complex physio-
pathology with possible diastolic and/or systolic
dysfunction. Huez and colleagues51 pointed out
RV diastolic dysfunction in SSc patients as well as
a decrease in pulmonary arterial compliance. Over-
beek and colleagues52 showed that for the same
level of PAP, SSc patients had lower RV systolic
function compared with patients with idiopathic
PAH; they also demonstrated that the RV systolic
response to an increase in PAP was poorest in
SSc patients. These studies highlight the impor-
tance of assessing RV systolic function in SSc pa-
tients, which unfortunately is often missing in
Table 1
Typical echocardiographic features in different pulmonary hypertension phenotypes in systemic
sclerosis
Pulmonary Arterial
Hypertension
Interstitial Lung Disease Left Cardiac Involvement
LV dimensions Normal to
reduced
Usually normal Usually increased
Left atrial
dimensions
Normal Normal Usually increased
RV-RA
dimensions
Increased Normal/increased Normal
Eccentricity
index
1–2 Usually <1.2 1
LV systolic
function
Normal Normal Reduced (ejection fraction
can be normal until later
stages)
LV diastolic
function
Normal, grade I Normal, grade I Grade II–-III
E/e’ usually <10 E/e’ usually <10 E/e’ usually >10
RV function Reduced Usually normal Usually normal (reduced in
biventricular involvement)
Mitral
regurgitation
Trivial–mild Trivial–mild Mild–moderate
TR Moderate–severe Mild–moderate Usually mild
sPAP 111 11 1
Inferior vena
cava
Dilated and fixed Usually normal
and collapsible
Normal and collapsible
PVR 111 1/11 Normal
Other signs  RV forming heart
apex
 Reduced ACT 
notch of RVOT
Doppler spectrum
 Pericardial effusion
Multiple diffuse B lines with
irregular pleural line at lung
ultrasound
Pericardial effusion
Abbreviations: E/e’, early mitral inflow velocity and mitral annular early diastolic velocity; 1, slightly increased; 11,
moderately increased; 111, highly increased.
Systemic Sclerosis 275echocardiographic reports.53 Echocardiographic
RV diastolic parameters can also be easily
assessed54 and have been shown significantly
different compared with control subjects.55 New
techniques for the assessment ofmyocardial defor-
mation have also been used to assess RV and RA
function in SSc,with significant results56–59; howev-
er, their use in routine clinical practice is still limited.
The addition of lung ultrasound to a standard
echocardiogram, adding only a few minutes
to the examination, may reveal the presenceof sonographic signs of pulmonary intersti-
tial involvement (sonographic B-lines) which,
when associated with an irregular pleural line, are
highly suggestive for ILD and may have a role in
the screening algorithm60,61 (see Table 1).Exercise Echocardiography
There is increasing awareness of the clinical rele-
vance of an abnormal pulmonary hemodynamic
response during exercise,62 but several questions
Gargani et al276remain to be elucidated; therefore, exercise PH is
an entity that has not been endorsed by the latest
European Guidelines, where its definition, even
when estimated by RHC, has been considered un-
supported due to insufficient data.3 More recently,
exercise PH has been defined as the presence of
resting mPAP less than 25 mm Hg and mPAP
greater than 30 mm Hg during exercise with total
pulmonary resistance greater than 3 Wood units,
during RHC.62 Exercise PH seems to represent
the hemodynamic manifestation of early pulmo-
nary vascular disease, left heart disease, lung dis-
ease, or a combination of these conditions,62
acting as a possible transitional phase anticipating
resting PH.
Exercise echocardiography is a noninvasive tool
to estimate pulmonary hemodynamics during ex-
ercise and is useful to assess abnormalities of pul-
monary vascular function as well as the state of the
right heart, although it does not have an estab-
lished role in the management of SSc patients. A
main issue in SSc is the high percentage of pa-
tients showing exercise PH during exercise stress
echocardiography, which clearly overestimates
the subset of SSc patients who will develop
PAH.63–66 PAP is dependent, however, not only
on PVR, which is abnormally increased in PAH,
but also on left atrial pressure and CO, as shown
both in healthy subjects67 and in SSc.51 It is, there-
fore, crucial to define the relative hemodynamic
contribution of each parameter to better under-
stand the main determinants of increased
PAP.68,69 Exercise echocardiography may identify
a subset of SSc patients without PH with an inap-
propriate exercise-induced increase in pulmonary
arterial systolic pressure (PASP) and early signs
of RV dysfunction. A study68 enrolling 172 consec-
utive SSc patients in New York Heart Association
class I/II showed a higher exercise-induced sPAP
(36.9  8.7 vs 25.9  3.3 mm Hg; P<.0001) and
a lower cardiac index increase (2.8  1.2 vs
4.6  2.3 L/min/m2; P<.0001) than controls.
In a population of 164 SSc patients, the authors
demonstrated that exercise PH (defined as an ex-
ercise sPAP 50 mm Hg and exercise PVR 3
Wood units during echocardiography) was present
in approximately half of the patients with normal
resting sPAP and was affected by age, ILD, and
RV and LV diastolic dysfunction, whereas only a
minority (5%) of these patients had an increase
in PVR during exercise, suggesting high heteroge-
neity of the pathophysiologic background.69 These
data were further confirmed in a smaller popula-
tion of 45 patients, where exercise PH was present
in 21 patients, with a positive correlation between
exercise sPAP and both exercise left atrial pres-
sure and exercise PVR (respectively, r2 5 0.61and r2 5 0.57; P<.05), again suggesting that exer-
cise PH was related to both increased exercise LV
filling pressure and exercise PVR.70 Thereby, exer-
cise echocardiography allows identification of
those patients with an abnormal increase in PAP
as well as a better understanding of the mecha-
nism leading to abnormal pulmonary hemody-
namic response during exercise.
Exercise echocardiography may also help
distinguish patients at risk of developing further
resting PH. Codullo and colleagues71 found that
a DsPAP cutoff of greater than 18 mm Hg, identi-
fied by receiver operating characteristic curve
analysis, had a sensitivity of 50% and a specificity
of 90% for the development of resting PH during
follow-up. In another study, exercise PH has
been found useful to predict the onset of resting
PH at echocardiography during follow-up, in addi-
tion to nailfold videocapillaroscopy.72 Exercise PH
with normal resting sPAP was present in 43% of
patients; after a mean follow-up of 24 months, 11
patients developed resting PH (as defined by
echocardiography), and all of them belonged to
the exercise PH group. Patients who did not
have exercise PH never developed a resting
sPAP greater than 35 mm Hg during the
follow-up.72
Kusunose and colleagues73 prospectively
enrolled 78 patients with CTD (including 70% of
SSc) with a baseline resting and postexercise
echocardiographic evaluation. During a median
follow-up of 32 months, 16 patients developed
resting PAH. The slope of mPAP/CO had an incre-
mental value over a 6-minute walking test distance
to predict PH at follow-up. Even though exercise
echocardiography is not included in the current
recommendations for screening patients at risk
of resting PH, it remains an interesting tool to
assess the physiopathology of the hemodynamic
behavior during stress, with a promising role in
the early detection of abnormal vascular response.
Moreover, an abnormal exercise-induced increase
in PASP may explain an otherwise inexplicable
effort dyspnea in SSc patients with normal base-
line hemodynamics.Nonechocardiographic Parameters
In the past few years, many studies have
addressed the complex issue of early diagnosis
in patients with SSc and in patients with CTD,
underlining the importance of a multiparametric
approach that should not be limited to transtho-
racic echocardiography as the sole instrumental
examination for establishing the likelihood of devel-
oping PAH,74 because other noninvasive screening
tests, such as pulmonary function tests (PFTs),
Box 1
Summary of general recommendations for
early detection of connective tissue disease–
associated pulmonary arterial hypertension
General recommendations
 All patients with SSc should be screened for
PAH.
 Patients with MCTD/CTD with scleroderma
features should be screened similarly to pa-
tients with SSc.
 Screening is not recommended for asymp-
tomatic patients with MCTD/CTD without
scleroderma features.
 All patients with SSc and MCTD/CTD with
scleroderma features with positive screening
results should be referred for RHC.
 RHC is mandatory for diagnosis of PAH.
Initial screening evaluation
 PFT with DLCO
 Transthoracic echocardiography
 NT-proBNP
 DETECT algorithm if DLCO less than 60% and
disease duration greater than 3 years
Frequency of noninvasive tests
 Transthoracic echocardiography annually as a
screening test
 Transthoracic echocardiography if new signs
or symptoms develop
 PFT with DLCO annually as a screening test
 PFT with DLCO if new signs or symptoms
develop
 NT-proBNP if new signs or symptoms develop
Abbreviation: MCTD, mixed CTD.
Adapted fromKhannaD,GladueH, Channick R, et al.
Recommendations for screening and detection of
connective-tissue disease associated pulmonary arterial
hypertension. Arthritis Rheum 2013;65(12):3196; with
permission.
Systemic Sclerosis 277andmeasurement of serum biomarkers, such as N-
terminal pro brain natriuretic peptide (NT-proBNP),
have been shown with PAH in SSc patients.75–77 In
particular, the Evidence-based detection of pulmo-
nary arterial hypertension in systemic sclerosis
(DETECT) study enrolled patients with more than
3 years’ disease duration from the first non–
Raynaud phenomenon symptom and a predicted
DLCO less than 60%, thus representing a high-
risk population. This was the first study on PAH
screening to undertake systematic RHC in all pa-
tients to develop an evidence-based algorithm for
earlier identification of PAH in amildly symptomatic
population. In this study, 466 patients underwent
noninvasive testing and RHC: results showed that
87 patients (19%) had RHC-confirmed PAH,
a higher prevalence compared with previous
studies.78 The DETECT algorithm showed a signif-
icantly higher sensitivity in identifying patients with
PAH,missing only 4% of patients as false negative.
Longitudinal data from this cohort have demon-
strated that 44% of the PAH patients who received
an early diagnosis through the DETECT algorithm
had disease progression during a relatively short
follow-up time, again underlining the clinical rele-
vance of early detection of PAH.79 The DETECT al-
gorithm has been successfully applied also to other
populations of high-risk patients.80 The DETECT al-
gorithm, however, is not applicable to patients with
a predicted DLCO greater than 60%. The PHAROS
also confirmed that a low DLCO less than 55% and
a high forced vital capacity % predicted to DLCO
%predicted ratio (FVC/DLCO) greater than 1.6
are good screening parameters in addition to
echo-derived sPAP in selecting those patients
who are at risk to develop SSc-PAH.81 More
recently, a study comparing the DETECT algorithm
with the screening models suggested by the 2009
and 2015 European Guidelines found that referring
patients to RHC according to the DETECT algo-
rithm yielded a high number of false-negative
cases but was useful especially to identify patients
with borderline PAP (mPAP 21–24mmHg),82 which
seems to be an intermediate stage on the contin-
uum between normal pulmonary hemodynamics
and PAH.83,84
Some recommendations for screening and
detection of CTD-associated PAH were published
in 2013, after a systematic review of the literature
by an international expert panel.74 This article con-
tains the first evidence-based and consensus-
based recommendations for screening and early
detection of CTD-associated PAH with the aim of
identifying patients with asymptomatic/preclinical
disease and those with mild symptoms to prevent
or delay progression of disease through early
management. Box 1 summarizes these generalrecommendations. It must be underlined that the
quality of evidence, which was assessed accord-
ing to the Grading of Recommendations Assess-
ment, Development and Evaluation Working
Group from very low to high, varies between the
different statements.
The recommendations established specific
criteria to recommend RHC in SSc and sclero-
derma spectrum disorders, which is advised in pa-
tients with (1) a TR jet velocity of 2.5 m/s–2.8 m/s
with signs and/or symptoms consistent with PH;
(2) a TR jet velocity of greater than 2.8 m/s with
Gargani et al278or without signs and/or symptoms of PH; (3) RA or
RV enlargement (RA major dimension >53 mm and
RV midcavity dimension >35 mm), irrespective of
TR jet velocity (including nonmeasurable
or <2.5 m/s); or (4) signs or symptoms of PH and
an FVC/DLCO greater than 1.6 and/or a predicted
DLCO of less than 60%, without an overt systolic
dysfunction, a greater than grade I diastolic
dysfunction, a greater than mild mitral or aortic
valve disease, or evidence of PH. The expert panel
did not recommend acute vasodilator testing dur-
ing RHC as part of the evaluation of PAH. This is
supported by the small number of patients in this
subset with both a positive vasodilator test result
(defined as a reduction in mPAP by at least
10 mmHg to an mPAP of <40 mmHg in the setting
of a normal CO) and a long-term response to
calcium-channel blockers.3,85
No clear recommendations are provided on
borderline mean PAP (21–24 mm Hg) or on exer-
cise PH, due to lack of long-term outcome data
and variability in exercise testing.86,87
The role of RV and RAmeasurements underlines
the importance of referring these patients to
specialized centers, where echocardiography is
performed by certified personnel, who will include
a thorough evaluation of the right heart.SUMMARY
Involvement of the right heart-pulmonary circula-
tion system is crucial in SSc and represents a
main prognostic determinant. PH may respond to
multiple and partially overlapping mechanisms of
precapillary and postcapillary etiologies. An early
diagnosis is mandatory to improve outcomes,
and a multidisciplinary and multiparametric
approach is required to fully understand the
diverse mechanisms leading to abnormal pulmo-
nary hemodynamics.
Recommendations on how to screen SSc-
related PAH have been established and may help
clinicians in this complex management, although
they are not meant to substitute a clinically driven
individualized assessment of the patient.REFERENCES
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